The peptide, endothelin-1 (ET-1) regulates proliferative responses in numerous cell types. Recently, a dual ET receptor antagonist was shown to prevent the increase in airway smooth muscle cell (SMC) proliferation that accompanies airway smooth muscle remodeling in a rat model of experimental asthma. Thus, we used [ 
Introduction
Asthma is currently viewed as a chronic inflammatory disease of the airways characterized by intermittent airflow obstruction and airway hyperresponsiveness (AHR), defined as exaggerated airway narrowing to a variety of stimuli [1] . Evidence suggests that one of the consequences of chronic inflammation is remodeling of the airways [2, 3] . Structural changes associated with remodeling include thickening of the subepithelium, increased collagen and proteoglycan deposition in the airway wall, and an increase in smooth muscle mass. Of these changes, mathematical modeling studies suggest that the increase in airway smooth muscle mass is the most important factor contributing to the 38 increased responsiveness of asthmatic airways [4] .
The increase in airway smooth muscle mass in asthma, which is due in part to increased numbers of airway smooth muscle cells (SMC), may be due to increased SMC proliferation, decreased SMC apoptosis, or a combination of the two. Many SMC survival factors and/or mitogens are expressed in asthmatic airways of humans or in the lungs of animals with experimentally induced allergic asthma [5] [6] [7] . Although the mediators of airway smooth muscle remodeling in asthma are not known, one potential candidate is endothelin-1 (ET-1). ET-1 levels are increased in the circulation and lungs of asthmatics, and ET-1 is both a mitogen and survival factor for SMC in culture [8] [9] [10] [11] . More direct evidence that ET-1 participates in airway smooth muscle remodeling was obtained by Fan Chung and colleagues using the Brown Norway (BN) rat model of experimental asthma [12] . In this model, repeated allergen challenge induces both an increase in airway smooth muscle mass as well as an increase in proliferation of airway SMC. Treatment of allergic BN rats with a dual ET receptor antagonist prevents the allergen-induced increase in proliferation of airway SMC [12] providing evidence that ET regulates airway smooth muscle remodeling in asthma.
ET-1, which was originally identified as a potent vasoconstrictor released from porcine endothelial cells [13] , binds with equal affinity to two ET receptors, ETA and ETB, both of which belong to the family of GPCRs [14, 15] . ET-1 induces proliferation of a variety of cells, including fibroblasts [16] [17] [18] and both vascular and airway SMC [19] [20] [21] [22] [23] . The cells that proliferate in response to ETs express the ETA receptor, the ETB receptor or both, and each ET receptor subtype can mediate cell proliferation [16, 24] . Each receptor subtype is expressed on airway smooth muscle cells [25, 26] . In addition to inducing cell proliferation alone, ET-1 synergistically enhances proliferation of cells induced by growth factors that activate receptor Tyr kinases (RTKs), such as epidermal growth factor (EGF) and platelet derived growth factor (PDGF) [20, 23, 27, 28] . Nevetheless, the mechanism by which ET-1 enhances RTK-induced proliferative responses is not well understood. Several growth factors, including EGF and PDGF are also expressed in the asthmatic lung [5] [6] [7] . Thus, the increase in airway smooth muscle mass in asthma may result from the combined effects of multiple mitogens, such as ET-1 and PDGF, possibly acting in synergy.
To better understand the mechanism by which ET-1 regulates proliferation of airway SMC we have investigated ET-1-dependent proliferative responses in cultured rat tracheal smooth muscle cells. Our data demonstrate that ET-1 alone induced activation of ERK 1/2 and induced moderate levels of [ 3 H]-thymidine (Thy) incorporation via pertussis toxin (PTX)-sensitive, as well as PTX-insensitive signaling pathways. ET-1 also potentiated PDGF-induced proliferative responses of rat tracheal SMC. The ability of ET-1 to enhance PDGFinduced proliferation did not correlate with enhanced activation of ERK 1/2, suggesting that ERK1/2 did not regulate the synergistic response. 1 induced activation of ERK 1/2 in both a concentrationdependent and a time-dependent manner ( Fig 1B) . Maximal activation of ERK 1/2 was induced with 100 nM ET-1 ( Fig 1B, top [30] [31] [32] . We are interested in identifying which G proteins mediate ETA receptor-dependent DNA synthesis and ERK 1/2 activation in tracheal SMC. One of the major effectors of activated G q is phospholipase C (PLC) β. Thus, to elucidate the role of PLC in ET-1-induced activation of ERK 1/2, SMC were pretreated with the PLC inhibitor, U-73122, prior to ET-1 stimulation. ET-1-induced activation of ERK 1/2 was attenuated in U-73122 pretreated cells by 39.0 ± 8% (Fig 3A) , suggesting that ET-1-induced ERK 1/2 activation is partially dependent upon PLC activity. Activated PLC hydrolyzes phosphoinositol 4,5-biphosphate (PIP 2 ) into 1,2-diacylglycerol (DAG), which activates conventional and novel isoforms of protein kinase C (PKC), and inositol 1,4,5-trisphosphate (IP 3 ), which induces release of calcium from the sarcoplasmic reticulum. We investigated the role of calcium and PKC in ET-1 induced ERK 1/2 activation and [ Fig 3B) . In fact there was a tendency toward an increase in ERK1/2 activation in BAPTA-AM treated cells, although this difference did not reach statistical significance (p = 0.09). These data indicate that calcium does not regulate ET-1-induced activation of ERK 1/2 in primary rat tracheal SMC. To investigate the role of PKC in the ability of ET-1 to activate ERK 1/2, SMC were exposed overnight to PMA (1 µM) to downregulate PKC and the ability of ET-1 to induce ERK 1/2 activation and [ activation of ERK 1/2 was inhibited following downregulation of PKC. ERK 1/2 activation decreased from 8.4 ± 1.2 fold to 2.7 ± 0.7 fold (Fig 4B) . These data demonstrate that Gq and its effector, PKC, regulate ETA receptor-dependent DNA synthesis and ERK 1/2 activation induced by ET-1.
Materials and Methods

Materials
Results
ET-1 induces activation of ERK 1/2 and [
To investigate if ET-1-induced ERK 1/2 activation and [ (Fig 5A) . Similarly, ET-1-induced ERK 1/2 activation was also partially inhibited in PTX-treated cells. Compared to vehicle treated cells, ET-1-induced ERK 1/ 2 activity in PTX-treated cells was significantly inhibited at 1, 5 and 10 minutes (Fig 5B) . Together, these data indicate that activation of G i/o regulates ET-1-induced [ One effector of G i , G q and G 12/13 is the low molecular weight G protein, Rho, which also regulates cell proliferation and ERK 1/2 activation in part via its target, Rho kinase [33, 34] . Increased expression of Rho protein in airway smooth muscle has been implicated in airway hyperresponsiveness of rats with experimental asthma one hour and subsequently stimulated with ET-1 (100 nM) for 5 min. Lysates were resolved by SDS-PAGE and immunoblotted with polyclonal anti-phosphoMAPK antibodies. This experiment was repeated three times and a representative result is shown. The percent maximum MAPK activation at five min ± SEM for the three experiments combined is presented; * p< 0.05 vs. ET-1-stimulated SMC. (B) Serum-deprived SMC were pretreated for 30 min with BAPTA-AM (10µM) and then stimulated with ET-1 (100 nM) for 5 min. Lysates were resolved by SDS-PAGE and immunoblotted with polyclonal anti-phosphoMAPK antibodies. This experiment was performed three times and a representative result is shown. The percent maximum MAPK activation at five minutes ± SEM for the three experiments combined is presented. Fig  5A) . Interestingly, however, inhibition of Rho kinase had no significant effect on the ability of ET-1 to induce maximal ERK 1/2 activation (Fig 5C) . These data indicate that Rho kinase differentially regulates ETA receptorinduced [ (Fig 6A) . Similarly, PDGF (1 ng/ml or 10 ng/ ml) also induced [ 3 H]-Thy incorporation in rat tracheal SMC (1.9 ± 0.2 fold and 4.6 ± 1.0 fold, respectively). In Activation of ERK 1/2 was assessed in SMC stimulated with ET-1 and/or PDGF in order to determine if the ability of ET-1 to potentiate PDGF-induced DNA synthesis correlated with potentiation of ERK 1/2 activation. We investigated if ET-1 altered the time course or magnitude of ERK 1/2 activation induced by PDGF (10 ng/ml) up to 24 hours post stimulation. Both ET-1 and PDGF induced activation of ERK 1/2 (Fig 6B) . However, ERK 1/2 activation did not differ in SMC stimulated with either PDGF or ET-1 alone (Fig 6B, upper and middle  panels) or with the combination of PDGF and ET-1 ( Fig  6B, lower panel) . These data suggest that the ability of ET-1 to potentiate PDGF-induced [ Finally, to demonstrate that the increase in DNA synthesis, assessed by [ 3 H]-Thy incorporation, reflected an increase in cell proliferation, quiescent SMC were stimulated with ET-1 (100 nM), PDGF (10 ng/ml), or both A B C Fig. 6 . ET-1 potentiates PDGF-induced DNA synthesis in tracheal SMC via MAPK independent pathway(s). (A) SMC were cultured until 70% confluent after which they were deprived of serum for 48h. SMC were then stimulated with ET-1 (10 nM or 100 nM) and/or PDGF (1 ng/ml or 10 ng/ml) for 24h. [
3 H]-Thy incorporation was then quantified by liquid scintillation counting. Results are mean ± SEM of six separate experiments, each done in triplicate. All stimuli induced DNA synthesis that was significantly greater than vehicle treated cells. * p <0.05 compared to SMC treated with 10 ng/ml PDGF alone. (B) Serum deprived SMC were stimulated with ET-1 (100 nM), or PDGF-BB (10 ng/ ml) for the indicated times. Lysates were resolved by 10% SDS-PAGE and immunoblotted with polyclonal anti-phosphoMAPK antibodies. This experiment was performed two times and a representative result is shown. over a seven-day time course (Fig 7) . Viable cell numbers were counted every other day. ET-1 induced a small increase in SMC number but the difference did not reach statistical significance. Consistent with PDGF being a potent SMC mitogen, following 3, 5 or 7 days of stimulation, PDGF induced a significant increase in SMC number. Significantly, ET-1 potentiated the PDGF-induced proliferative response at days 5 and 7. Following costimulation with PDGF and ET-1 for five days, there were 2.7 ± 0. Together, these data demonstrate that ET-1 potentiates both PDGF-induced DNA synthesis and proliferation of cultured rat tracheal SMC.
Discussion
In experimental models of asthma, two classes of mitogens that have been shown to regulate airway smooth muscle remodeling in vivo are leukotrienes and ET [12, 36, 37] . In addition to these growth factors, other smooth muscle mitogens, including PDGF, are present in the lungs of allergic individuals [5] [6] [7] . Thus, it is likely that the increase in SMC proliferation that contributes to asthma pathogenesis is due to the combined effects of several growth factors acting in concert. In addition to SMC proliferation, increased SMC survival, SMC hypertrophy as well as increased deposition of extracellular matrix within the smooth muscle layer may also contribute to the overall increase in smooth muscle mass in asthma [3] . Herein, we have investigated the mechanisms by which ET-1, with and without PDGF, regulates proliferative responses of cultured tracheal SMC. We have demonstrated that ET-1 alone induced ERK 1/2 activation and was weakly mitogenic for rat tracheal SMC. These data are consistent with those of Posada and colleagues who demonstrated that ERK 1/2 activation and DNA synthesis induced by ET-1 in rat tracheal SMC were attenuated upon inhibition of MEK with PD98059 [38] . Significantly, our data demonstrate that while ET-1 was only weakly mitogenic, ET-1 potentiated both [ 3 H]-Thy incorporation and SMC proliferation induced by PDGF, a more potent growth factor for SMC. Similar to data demonstrating that the ET receptors activate multiple G protein subunits in other cells [30] [31] [32] , our data suggest that ETA receptordependent DNA synthesis and ERK 1/2 activation in rat tracheal SMC were regulated by several G proteins. A role for G i/o is provided by our data demonstrating that ERK 1/2 activation was attenuated and DNA synthesis abrogated in ET-1 stimulated SMC that had been pretreated with PTX. A role for G q is provided by our data demonstrating that downregulation of PKC abrogated DNA synthesis and inhibited ERK 1/2 activation induced by ET-1. Similarly, in bovine tracheal smooth muscle cells ET-1-induced DNA synthesis and ERK 1/2 activation are inhibited by pretreatment with PTX or following PKC downregulation [21] . ET-1-induced DNA synthesis is also inhibited in myometrial cells and immortalized Rat-1 fibroblasts following PKC downregulation [17, 39, 40] . On the other hand, PTX has no effect on ET-1 induced, ETA receptor-dependent DNA synthesis in renal mesangial cells [41] . In addition, while we found that inhibition of phosphoinositide 3-kinase by pretreatment of SMC with LY294002 had no effect on ET-1 induced ERK 1/2 activation or DNA synthesis in rat tracheal SMC (data not shown), inhibition of phosphoinositide 3-kinase abolishes ET-1-induced, ETA receptor-dependent DNA synthesis in NIH3T3 fibroblasts [42] and attenuates ET-1 induced ERK1 activation in human embryonic kidney cells expressing ETA receptor [43] . Together, these data provide evidence that ETA receptor induces DNA synthesis and ERK1/2 activation via different signaling pathways in different cell types.
In addition to protein kinase C, our data demonstrate that Rho kinase also regulated ET-1-induced DNA synthesis in cultured rat tracheal SMC. Rho kinase is activated by the low molecular weight GTPase Rho, which is expressed at higher levels in the bronchial smooth muscle and contributes to airway hyperresponsiveness in rats with experimental asthma [35] . Nevertheless, it is not known if airway smooth muscle remodeling in vivo is regulated by Rho or Rho kinase. Both Rho and Rho kinase have been implicated in vascular remodeling, characterized in part by increased vascular SMC proliferation, in animal models of hypertension [34, 44, 45] [33] .
While ET-1 potentiated SMC proliferation and [
3 H]-Thy incorporation induced by PDGF, the time course and magnitude of ERK 1/2 activation induced by ET-1 and PDGF together did not differ from that in SMC treated with PDGF or ET-1 alone. These data suggest that signaling pathways other than ERK 1/2 regulate the ability of ET-1 to potentiate PDGF-induced proliferative responses in rat tracheal SMC. In addition to ET-1, other GPCR agonists potentiate cell proliferation and/or DNA synthesis induced by receptor tyrosine kinase activation [20, 23, 27, 28, 47, 48] . The signaling pathways targeted when GPCRs enhance proliferative responses of airway SMC may differ depending upon the species as well as which GPCR is activated. For example, while our data suggest that ERK 1/2 activation is not involved, ET-1-dependent enhancement of EGF-induced proliferation of guinea pig airway SMC and rat myometrial cells correlates with enhanced activation of ERK 1/2 activation [20, 39] . The ability of thrombin to enhance proliferation of human airway SMC induced by EGF does not appear to be mediated by ERK 1/2 activation but instead correlates with synergistic activation of p70 S6 kinase [28] . Lysophosphatidic acid-dependent enhancement of EGF-induced proliferation of human airway SMC also does not correlate with ERK 1/2 activation. However, in this case, the low molecular weight G protein, Rho, appears to mediate the synergistic response, whereas p70 S6 kinase does not [49] . The effectors of p70 S6 kinase and Rho that mediate these synergistic proliferative responses have not been identified. How these growth factors regulate the cell cycle machinery and transition past the restriction point of the cell cycle is also not clear. Indeed, the molecular mechanism by which activation of GPCRs potentiates cell proliferation induced by receptor tyrosine kinase activation is poorly understood.
In conclusion, we have investigated signaling pathways that regulate the ability of ET-1 to induce proliferative responses in cultured rat tracheal SMC. Our data demonstrate that ET-1-induced activation of ETA receptor in rat tracheal SMC regulates ERK 1/2 activation and DNA synthesis via both PTX-sensitive and PTXinsensitive pathways. Protein kinase C and Rho kinase each regulated ET-1-dependent SMC DNA synthesis. While ET-1 was only weakly mitogenic when used alone it potentiated proliferative responses induced by PDGF. Both ET-1 and PDGF are present in the lungs of asthmatics and thus may contribute to airway smooth muscle remodeling in asthma. Further defining the G proteins and signaling pathways that regulate ET-1-dependent proliferative responses in airway SMC may provide us with unique targets to treat or prevent airway smooth muscle remodeling in asthma.
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